Xeris Biopharma (XERS) Short Interest Ratio & Short Volume $6.84 +0.24 (+3.64%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.82 -0.02 (-0.29%) As of 08/8/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Xeris Biopharma Short Interest DataXeris Biopharma (XERS) has a short interest of 19.55 million shares. This marks a 164.55% increase in short interest from the previous month. The short interest ratio (days to cover) is 9.1, indicating that it would take 9.1 days of the average trading volume of 2.36 million shares to cover all short positions.Current Short Interest19,550,000 sharesPrevious Short Interest7,390,000 sharesChange Vs. Previous Month+164.55%Dollar Volume Sold Short$103.42 millionShort Interest Ratio9.1 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares156,380,000 sharesPercentage of Shares Shorted12.50%Today's Trading Volume11,441,459 sharesAverage Trading Volume2,356,814 sharesToday's Volume Vs. Average485% Short Selling Xeris Biopharma? Sign up to receive the latest short interest report for Xeris Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartXERS Short Interest Over TimeXERS Days to Cover Over TimeXERS Percentage of Float Shorted Over Time Xeris Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202519,550,000 shares $103.42 million +164.6%N/A9.1 $5.29 6/30/20257,390,000 shares $34.51 million -58.8%5.1%5.8 $4.67 6/15/202517,940,000 shares $78.04 million +1.9%12.3%6.9 $4.35 5/31/202517,600,000 shares $86.77 million -1.1%12.4%5.8 $4.93 5/15/202517,800,000 shares $85.26 million +3.3%12.5%5.8 $4.79 4/30/202517,230,000 shares $78.74 million -9.6%N/A5.6 $4.57 4/15/202519,050,000 shares $83.44 million +11.8%13.4%6.5 $4.38 3/31/202517,040,000 shares $93.55 million +52.0%12.0%6.1 $5.49 3/15/202511,210,000 shares $54.03 million +5.5%7.9%4.8 $4.82 2/28/202510,630,000 shares $40.71 million +3.5%7.5%5.5 $3.83 Get the Latest News and Ratings for XERS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. 2/15/202510,270,000 shares $36.87 million -2.1%7.2%6.3 $3.59 1/31/202510,490,000 shares $37.34 million +1.3%N/A6.2 $3.56 1/15/202510,360,000 shares $33.57 million +1.7%N/A6.3 $3.24 12/31/202410,190,000 shares $34.54 million +7.0%N/A6.4 $3.39 12/15/20249,520,000 shares $31.23 million -3.9%N/A6.1 $3.28 11/30/20249,910,000 shares $32.50 million -2.4%N/A6.1 $3.28 11/15/202410,150,000 shares $29.64 million -10.7%N/A6.4 $2.92 10/31/202411,370,000 shares $36.61 million -1.7%N/A7.2 $3.22 10/15/202411,570,000 shares $34.94 million +4.3%N/A7.7 $3.02 9/30/202411,090,000 shares $31.61 million +0.8%N/A7.2 $2.85 9/15/202411,000,000 shares $31.68 million +2.7%N/A7.1 $2.88 8/31/202410,710,000 shares $30.10 million -0.9%N/A7.6 $2.81 8/15/202410,810,000 shares $28.32 million -3.7%N/A7.5 $2.62 7/31/202411,220,000 shares $27.83 million -1.7%N/A7.9 $2.48 7/15/202411,410,000 shares $28.30 million +3.7%N/A8.7 $2.48 6/30/202411,000,000 shares $24.75 million -0.8%N/A8.2 $2.25 6/15/202411,088,000 shares $24.39 million -2.1%N/A7.9 $2.20 5/31/202411,330,000 shares $25.55 million +5.0%N/A7.3 $2.26 5/15/202410,790,000 shares $21.36 million +11.9%N/A6.4 $1.98 4/30/20249,640,000 shares $16.87 million +7.8%N/A5.2 $1.75 4/15/20248,940,000 shares $16.54 million -0.5%N/A4.8 $1.85 3/31/20248,980,000 shares $19.85 million -2.8%N/A4 $2.21 3/15/20249,240,000 shares $20.61 million -4.2%N/A4 $2.23 2/29/20249,640,000 shares $29.64 million +2.3%N/A4.2 $3.08 2/15/20249,420,000 shares $30.24 million +0.2%N/A4.6 $3.21 1/31/20249,400,000 shares $23.12 million -9.7%N/A4.7 $2.46 1/15/202410,410,000 shares $28.84 million +8.3%N/A5.5 $2.77 12/31/20239,610,000 shares $22.58 million +18.4%N/A6.6 $2.35 12/15/20238,120,000 shares $16.40 million -1.2%N/A6.2 $2.02 11/30/20238,220,000 shares $15.29 million -8.2%N/A7 $1.86The Coin That Could Define Trump’s Crypto Presidency (Ad)When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”Discover the coin that could define Trump’s crypto presidency. 11/15/20238,950,000 shares $13.16 million +14.9%N/A8.1 $1.47 10/31/20237,790,000 shares $14.26 million +2.4%N/A8.4 $1.83 10/15/20237,610,000 shares $12.02 million -4.0%N/A8 $1.58 9/30/20237,930,000 shares $14.75 million +0.6%N/A8.4 $1.86 9/15/20237,880,000 shares $15.76 million +6.2%N/A7.5 $2.00 8/31/20237,420,000 shares $16.84 million -12.9%N/A6.9 $2.27 8/15/20238,520,000 shares $19.00 million +2.7%N/A7.8 $2.23 7/31/20238,300,000 shares $21.66 million -2.6%N/A7.1 $2.61 7/15/20238,520,000 shares $21.64 million +0.4%N/A7.2 $2.54 6/30/20238,490,000 shares $22.24 million -5.0%N/A6.5 $2.62 6/15/20238,940,000 shares $24.23 million +13.6%N/A6.7 $2.71 5/31/20237,870,000 shares $20.15 million -5.5%N/A6.2 $2.56 5/15/20238,330,000 shares $23.66 million -1.9%N/A6.3 $2.84 4/30/20238,490,000 shares $19.19 million +6.3%N/A6.9 $2.26 4/15/20237,990,000 shares $17.34 million +2.0%N/A7 $2.17 3/31/20237,830,000 shares $12.76 million -5.4%N/A6.7 $1.63 3/15/20238,280,000 shares $10.76 million +20.9%N/A7.6 $1.30 2/28/20236,850,000 shares $9.45 million +13.4%N/A6.9 $1.38 2/15/20236,040,000 shares $7.61 million -6.9%N/A6.8 $1.26 1/31/20236,490,000 shares $8.05 million +9.1%N/A7.7 $1.24 1/15/20235,950,000 shares $7.62 million +1.9%N/A6.8 $1.28 12/30/20225,840,000 shares $7.77 million +2.5%N/A6.5 $1.33 12/15/20225,700,000 shares $7.64 million -0.7%N/A7.3 $1.34 11/30/20225,740,000 shares $8.61 million -9.5%N/A7 $1.50 11/15/20226,340,000 shares $8.81 million +0.8%N/A7.7 $1.39 10/31/20226,290,000 shares $10.06 million +0.8%N/A7.6 $1.60 10/15/20226,240,000 shares $7.61 million -5.5%N/A7.2 $1.22 9/30/20226,600,000 shares $10.30 million -21.6%N/A8 $1.56 9/15/20228,420,000 shares $15.07 million -8.1%N/A8 $1.79 8/31/20229,160,000 shares $15.30 million -4.8%N/A8.3 $1.67 8/15/20229,620,000 shares $18.18 million -7.1%N/A7.5 $1.89 7/31/202210,350,000 shares $14.70 million +4.9%N/A6.1 $1.42 7/15/20229,870,000 shares $14.11 million -3.3%N/A5.5 $1.43 6/30/202210,210,000 shares $15.72 million +64.7%N/A5.6 $1.54 6/15/20226,200,000 shares $10.91 million -8.3%N/A3.3 $1.76 5/31/20226,760,000 shares $14.94 million +9.0%N/A3.7 $2.21 5/15/20226,200,000 shares $10.60 million +14.6%N/A3.4 $1.71 4/30/20225,410,000 shares $13.20 million +20.2%N/A3.3 $2.44 4/15/20224,500,000 shares $11.03 million +12.8%N/A2.6 $2.45 3/31/20223,990,000 shares $10.21 million -23.4%N/A2.1 $2.56 3/15/20225,210,000 shares $13.91 million -1.7%N/A1.7 $2.67 2/28/20225,300,000 shares $12.61 million -17.3%N/A1.8 $2.38 2/15/20226,410,000 shares $16.47 million -3.5%N/A2.1 $2.57 1/31/20226,640,000 shares $14.01 million +41.6%N/A2.1 $2.11 1/15/20224,690,000 shares $10.41 million +27.5%N/A1.5 $2.22 12/31/20213,680,000 shares $10.78 million +4.3%N/A0 $2.93 12/15/20213,530,000 shares $8.01 million +16.1%N/A1.9 $2.27 11/30/20213,040,000 shares $6.35 million -30.9%N/A1.8 $2.09 11/15/20214,400,000 shares $10.91 million +14.6%N/A2.4 $2.48 10/29/20213,840,000 shares $7.14 million +13.6%N/A1.1 $1.86The Coin That Could Define Trump’s Crypto Presidency (Ad)When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”Discover the coin that could define Trump’s crypto presidency. 10/15/20213,380,000 shares $6.76 million -17.2%N/A1 $2.00 9/30/20214,080,000 shares $10.00 million -5.1%N/A1.2 $2.45 9/15/20214,300,000 shares $10.97 million -12.1%6.6%1.2 $2.55 8/31/20214,890,000 shares $13.50 million +9.9%7.6%1.2 $2.76 8/13/20214,450,000 shares $10.32 million -17.3%6.9%1 $2.32 7/30/20215,380,000 shares $16.52 million +0.6%8.2%1.8 $3.07 7/15/20215,350,000 shares $18.89 million -60.1%8.3%1.8 $3.53 6/30/202113,400,000 shares $54.54 million -13.9%20.7%4.4 $4.07 6/15/202115,570,000 shares $64.46 million +1.8%24.0%5.4 $4.14 5/28/202115,290,000 shares $47.70 million +0.1%23.6%5.2 $3.12 5/14/202115,270,000 shares $48.71 million +14.4%N/A6.4 $3.19 4/30/202113,350,000 shares $51.66 million -1.6%N/A5.3 $3.87 4/15/202113,560,000 shares $55.19 million -1.1%N/A5.2 $4.07 3/31/202113,710,000 shares $57.72 million +29.1%N/A5 $4.21 3/15/202110,620,000 shares $51.08 million +24.8%N/A3.9 $4.81 2/26/20218,510,000 shares $46.08 million +44.5%N/A3.6 $5.42 2/12/20215,890,000 shares $39.05 million +22.0%N/A2.7 $6.63 1/29/20214,830,000 shares $25.16 million -10.6%N/A2.4 $5.21 1/15/20215,400,000 shares $31.00 million +6.3%N/A3.1 $5.74 12/31/20205,080,000 shares $25.96 million -3.8%N/A2.9 $5.11 12/15/20205,280,000 shares $24.50 million -22.8%N/A3.1 $4.64 11/30/20206,840,000 shares $30.99 million -53.8%N/A3.5 $4.53 10/30/202014,500,000 shares $71.34 million -18.0%N/A4.6 $4.92 10/15/202017,680,000 shares $94.94 million +0.9%N/A5.1 $5.37 9/30/202017,530,000 shares $103.95 million +9.5%N/A4.7 $5.93 9/15/202016,010,000 shares $88.86 million -3.7%N/A3.7 $5.55 8/31/202016,620,000 shares $78.11 million +9.2%N/A4.3 $4.70 8/14/202015,220,000 shares $63.77 million +14.6%N/A4.7 $4.19 XERS Short Interest - Frequently Asked Questions What is Xeris Biopharma's current short interest? Short interest is the volume of Xeris Biopharma shares that have been sold short but have not yet been closed out or covered. As of July 15th, investors have sold 19,550,000 shares of XERS short. Learn More on Xeris Biopharma's current short interest. What is a good short interest ratio for Xeris Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XERS shares currently have a short interest ratio of 9.0. Learn More on Xeris Biopharma's short interest ratio. Which institutional investors are shorting Xeris Biopharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Xeris Biopharma: Simplex Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Xeris Biopharma's short interest increasing or decreasing? Xeris Biopharma saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 19,550,000 shares, an increase of 164.5% from the previous total of 7,390,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Xeris Biopharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Xeris Biopharma: HUTCHMED (China) Limited Sponsored ADR (0.20%), Kymera Therapeutics, Inc. (11.62%), Crinetics Pharmaceuticals, Inc. (13.07%), Immunovant, Inc. (29.97%), Alvotech (1.55%), Organon & Co. (5.68%), NewAmsterdam Pharma Company N.V. (11.06%), Recursion Pharmaceuticals, Inc. (34.95%), Ultragenyx Pharmaceutical Inc. (9.13%), Mirum Pharmaceuticals, Inc. (13.10%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Xeris Biopharma stock? Short selling XERS is an investing strategy that aims to generate trading profit from Xeris Biopharma as its price is falling. XERS shares are trading up $0.24 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Xeris Biopharma? A short squeeze for Xeris Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of XERS, which in turn drives the price of the stock up even further. How often is Xeris Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XERS, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies HCM Short Interest Data KYMR Short Interest Data CRNX Short Interest Data IMVT Short Interest Data ALVO Short Interest Data OGN Short Interest Data NAMS Short Interest Data RXRX Short Interest Data RARE Short Interest Data MIRM Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:XERS) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XERS Stock Alerts